Author

Kanam Malhotra

Institution: AstraZeneca (United States)

Observed institutions: Sensei Biotherapeutics (United States), AstraZeneca (United States), Panjab University

ORCID: 0009-0003-2712-7634

Observed ORCID: 0009-0003-2712-7634

OpenAlex ID: A5072194635

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

2024 · Thomas Thisted, F. Donelson Smith, et al. · Nature Communications · 48

PDF

Copper and dyes enhance laccase production in γ-proteobacterium JB

2004 · Kanam Malhotra, Prince Sharma, et al. · Biotechnology Letters · 27

SNS-101, a highly selective monoclonal antibody against the active form of VISTA, demonstrates significantly reduced cytokine release.

2022 · Edward van der Horst, Zhi-Gang Jiang, et al. · Journal of Clinical Oncology · 5

Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target

2021 · Noa G. Holtzman, Michael S. Lebowitz, et al. · Frontiers in Oncology · 5

PDF

228 Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity

2021 · Thomas Thisted, Arnab Mukherjee, et al. · Regular and Young Investigator Award Abstracts · 5

PDF

856 SNS-101, a highly pH-selective VISTA:PSGL-1 inhibitory antibody, potentiates anti-PD-1 sensitivity, expands memory T-cells and enhances tumor infiltration of CD8 T-cells

2022 · Thomas Thisted, Tim Eitas, et al. · Regular and Young Investigator Award Abstracts · 3

PDF

Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-cell Activation

2025 · Thomas Thisted, F. Donelson Smith, et al. · Cancer Immunology Research · 2

483 Dual blockage of PD-1 and TIGIT with rilvegostomig inhibits tumor growth in various in vitro/in vivo/ex vivo tumor models through effector CD8 activation and immune modulation

2024 · Paul Chariou, Raymond Rothstein, et al. · Regular and Young Investigator Award Abstracts · 2

Aspartate Beta-Hydroxylase (ASPH) As a Novel Therapeutic Target in Acute Myeloid Leukemia

2018 · Noa G. Holtzman, Michael S. Lebowitz, et al. · Blood · 2

Immunogenicity of a lambda phage-based anti-cancer vaccine targeting HAAH

2013 · Steven Fuller, Solomon Stewart, et al. · Journal for ImmunoTherapy of Cancer · 2

PDF

Post-transcriptional Silencing of Ga20ox1 in Potato

2005 · Kanam Malhotra, Sandhya Agarwal, et al. · Potato Journal · 2

Dual Targeting for Enhanced Tumor Immunity: Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-Cell Activation

2025 · Thomas Thisted, F. Donelson Smith, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1

PDF

Abstract 5294: Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy

2024 · Thomas Thisted, Zhi-Gang Jiang, et al. · Cancer Research · 1

485 Functional characterization of the inhibitory activity and identification of novel T-cell receptors for the tumor-associated macrophage receptor VSIG4

2022 · Tim Eitas, Edward van der Horst, et al. · Regular and Young Investigator Award Abstracts · 1

PDF

Inhibition of tumor growth in vivo by a nanoparticle-based therapeutic cancer vaccine targeting HAAH

2013 · Steven Fuller, Solomon Stewart, et al. · Journal for ImmunoTherapy of Cancer · 1

PDF

Design, development and production of nano-particle-based anticancer vaccine targeting human aspartyl (asparaginyl) β-hydroxylase (HAAH)

2013 · Biswajit Biswas, Solomon Stewart, et al. · Journal for ImmunoTherapy of Cancer · 1

PDF

Abstract 5546: Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-PD-1 monotherapy in models of HNSCC

2026 · Jun Ren, Ngan Mitchell, et al. · Cancer Research

Figure S2 from Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-cell Activation